研究方向
药物化学生物学，聚焦开发共价活性小分子调控生物大分子的生物功能，具体包括发展新型共价药物开发策略、开发可调控蛋白蛋白相互作用的功能分子和可解析蛋白生物功能的探针分子。
本课题组长期欢迎具有有机合成、分子和细胞生物学、蛋白质组学的博士后、研究生加入，同时欢迎对我们研究方向感兴趣的本科生加入。
教育与工作经历
2008-2012 四川大学，工学学士
2012-2018北京大学，理学博士
2019-2024新加坡国立大学，博士后研究员
2025 - 至今 中山大学，药学院（深圳），副教授，博导
代表性学术论文
[1] Guanghui Tang, #* Xuan Wang, # Huisi Huang, Manyi Xu, Xingyu Ma, Fengfei Miao, Xiaoyun Lu, Liqian Gao, Chong-Jing Zhang, Zhi-Min Zhang,* and Shao Q. Yao.* Small Molecule-Induced Posttranslational Acetylation of Catalytic Lysine of Kinases in Mammalian Cells. Journal of the American Chemical Society, 2024, 146, 34, 23978–23988.
[2] Guanghui Tang,#* Wei Wang,# Chengjun Zhu,# Huisi Huang, Peng Chen, Xuan Wang, Manyi Xu, Jie Sun, Chong-Jing Zhang, Qicai Xiao, Liqian Gao, Zhi-Min Zhang,* and Shao Q. Yao.* Global Reactivity Profiling of the Catalytic Lysine in human kinome for Development of Potential Targeted Covalent Inhibitors. Angewandte Chemie International Edition,2024, e202316394.
[3] Peng Chen,#Guanghui Tang,#* Chengjun Zhu, # Jie Sun, Xuan Wang, Menghua Xiang, Huisi Huang, Wei Wang, Lin Li, Zhi-Min Zhang*, Liqian Gao*, and Shao Q. Yao*. 2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases. Journal of the American Chemical Society,2023, 145, 7, 3844–3849.
[4] Guanghui Tang, # Wei Wang, # Xuan Wang, Ke Ding, SoFong Cam Ngan, Jiao-Yu Chen, Siu Kwan Sze, Liqian Gao, Peiyan Yuan,* Xiaoyun Lu,* Shao Q. Yao*. Cell-Active, Irreversible Covalent Inhibitors that Selectively Target the Catalytic Lysine of EGFR by Using Fluorosulfate-Based SuFEx Chemistry. European Journal of Medicinal Chemistry, 2023, 259, 115671.
[5] Guanghui Tang, Lihong Liu, Xueying Wang, Zhengying Pan.* Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as irreversible covalent inhibitors of Interleukin-2 inducible T cell kinase(Itk). European Journal of Medicinal Chemistry,2019, 173:167-183.
[6] Peng Chen,#Jie Sun,# Cheng-Jun Zhu,#Guanghui Tang,* Wei Wang, Manyi Xu, Menghua Xiang, Chong-Jing Zhang, Zhi-Min Zhang,* Liqian Gao,* Shao Q. Yao.* Cell-Active, Reversible and Irreversible Covalent Inhibitors that Selectively Target the Catalytic Lysine of BCR-ABL Kinase.Angewandte Chemie International Edition, 2022, 61, e202203878.
[7] Guanghui Tang,# Ying-Jie Lim,#* Wei Wang, Zi Ye, Chong-Jing Zhang and Shao Q. Yao*. Orthogonal Strategies for Profiling Potential Cellular Targets of Anandamide and Cannabidiol, Chemistry–A European Journal, 2023, 29, e202300682.
[8] Ying-Jie Lim,#Guanghui Tang,# Zi Ye, Chong-Jing Zhang, Jie Wu* and Shao Q. Yao*. A Late-Stage Aryl C-H Olefination Strategy and Its Application Towards Global Proteome Profiling of ∆8-Tetrahydrocannabinol. Chemistry–A European Journal,2023, 29, e202300531.
[9] Wei Wang,# Xuan Wang,#Guanghui Tang,* Chengjun Zhu, Menghua Xiang, Qicai Xiao, Zhi-Min Zhang,* Liqian Gao* and Shao Q Yao.* Multitarget inhibitors/probes that target LRRK2 and AURORA A kinases noncovalently and covalently. Chemical Communications, 2023, 59, 10789-10792.
